AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01077739
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: standard FOLFOX regimen
Trial: NCT01077739
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard XELOX regimen
Trial: NCT02824601
Drug: Calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-visit-treatment (n=12): Chemomechanical preparation (CMP) + Ca(OH)2 + SSL medication for 14-days + PDT. CMP was performed by using the single-file reciprocating technique + 2.5% NaOCL and 17% EDTA. Methylene blue was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after 14-days of intracanal medication
Trial: NCT04413552
Drug: INDV-2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INDV-2000 will be administered as either powder in solution or powder in capsule, depending on dose administered.
Trial: NCT04413552
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as either powder in solution or powder in capsule, depending on dose administered.
Trial: NCT01790828
Drug: Xyntha : coagulation factor IIIV (recombinant)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xyntha will be administered according to physician's discretion.
Trial: NCT00877071
Drug: LC Bead loaded with doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC Bead is a new product specifically designed for TACE. LC Bead microspheres will be loaded with between 50-100mg of doxorubicin for each of several TACE procedures. The bead will utilize embolic induced ischemia as well as local chemotherapy in an effort to downstage unresectable HCC to liver transplantation
Trial: NCT00264069
Drug: antipsychotic
RxNorm normalized name: ANTIPSYCHOTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as prescribed
Trial: NCT00264069
Drug: antidepressants
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as prescribed
Trial: NCT01275755
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01275755
Drug: ADL5945 0.25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02544464
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (normal saline) is administered after anesthesia induction
Trial: NCT04098406
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was liquid with identical color and taste
Trial: NCT00102141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, given as tablets orally once daily in the morning for 8 weeks
Trial: NCT01073670
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin was given via suppository at time of induction for anesthesia (2 x 50 mg) followed by one 50 mg suppository at 6, 12, 18 and 24 hours following cardiac bypass surgery.
Trial: NCT01073670
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were given a loading dose of 2600 mg of acetaminophen (via suppository) at time of induction for anesthesia then given 1300mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
Trial: NCT00375362
Drug: Nitroderm patch
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02020122
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non active placebo
Trial: NCT02416128
Drug: Euphrasia
RxNorm normalized name: Euphrasia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in the treated eye QID X 10 days
Trial: NCT02416128
Drug: Prednisolone acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 drop in the treated eye QID X 10 days
Trial: NCT03482297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo will be given three times a day on the baseline day (placebo)
Trial: NCT03281187
Drug: Nasotestt 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 114 participants randomized to this arm must administer one packet of testosterone 5 mg nasal gel (Nasotestt) in each nostril 3 times a day for 60 days.
Trial: NCT03030989
Drug: Placebo Wipe
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00090701
Drug: AG2037
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01671072
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium chloride 0.9%, 3.5ml
Trial: NCT01690000
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 or 3 mg of melatonin PO each night for 12 months
Trial: NCT01697605
Drug: BGJ398
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02205255
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
Trial: NCT02205255
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02161484
Drug: Ropivacine 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm.
Trial: NCT02691013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04704492
Drug: Biological: SM03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological: SM03 600 mg or 900 mg intravenous (IV) on week 0,2
Trial: NCT01955772
Drug: Enteral nutrition alanyl-glutamin, Dipeptiven
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutrition versus parenteral nutrition
Trial: NCT00546156
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy regimen
Trial: NCT01730534
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose (od)
Trial: NCT00546156
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard chemotherapy regimen
Trial: NCT01647516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02394496
Drug: Aromatase Inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as indicated in the Summary Product Characteristic
Trial: NCT03395470
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: DDI
Trial: NCT01493687
Drug: CD5024
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD5024 1% Cream, once daily
Trial: NCT00162409
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00089141
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01053962
Drug: SP-304 9.0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP-304 9.0 mg
Trial: NCT01053962
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01163643
Drug: 0.3% BOL-303242-X ophthalmic suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% BOL-303242-X ophthalmic suspension BID for 12 weeks.
Trial: NCT01163643
Drug: 2% BOL-303242-X ophthalmic suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% BOL-303242-X ophthalmic suspension BID for 12 weeks.
Trial: NCT03896737
Drug: Daratumumab plus Velcade Cyclophosphamide Dexamethasone
RxNorm normalized name: Velcade
DrugBank: Bortezomib D-mannitol (DB16741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.
Trial: NCT01163643
Drug: Placebo Comparator: Vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator: Vehicle BID for 12 weeks.
Trial: NCT01163643
Drug: 1% BOL-303242-X ophthalmic suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% BOL-303242-X ophthalmic suspension BID for 12 weeks.
Trial: NCT00880061
Drug: IL13-PE38QQR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01163643
Drug: 2% BOL-303242-X ophthalmic suspension AM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% BOL-303242-X ophthalmic suspension once daily (QD) AM and vehicle QD in PM for 12 weeks.
Trial: NCT01163643
Drug: 2% BOL-303242-X ophthalmic suspension PM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle QD AM and 2% BOL-303242-X ophthalmic suspension QD in PM for 12 weeks.
Trial: NCT03171480
Drug: Monoket Pill
RxNorm normalized name: Monoket Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-vaginal application of Monoket as a cervical ripening agent for pregnant women undergoing induction of labor
Trial: NCT03171480
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The pharmacy has compounded an identical appearing placebo
Trial: NCT01077609
Drug: Intermittent, sub-chronic and chronic Flixonase use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent exposure episode is a series of fewer than four sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
Trial: NCT01077609
Drug: Intermittent, sub-chronic and chronic use of intranasal steroids other than Flixonase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent exposure episode is a series of fewer than four sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for an intranasal steroid other than Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
Trial: NCT03580590
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Tablet
Trial: NCT04141631
Drug: EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min)
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min) will be administered if~* Hb \< 13g/dL the day before surgery~* Hb ≥ 7g/dL AND ScvO2 \> 65% in postoperative ICU stay~Postoperative Transfusion will be guided by ScvO2 values :~if Hb ≤ 8 g/dL AND ScvO2 ≤ 65% or if Hb \< 7g/dL independently of ScVO2 value
Trial: NCT00019058
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03699462
Drug: Plasma solution-A injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The group receiving balanced crystalloid solution (Plasma solution-A injection, CJ Pharma, South Korea) during surgery
Trial: NCT03699462
Drug: 5% Albumin
RxNorm normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The group receiving 5% albumin (Albumin 5% inj, Green cross, South Korea) during surgery
Trial: NCT02833844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of matching placebo QM
Trial: NCT01051544
Drug: FVIII/VWF concentrates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be centrally randomized to receive a FVIII/VWF concentrate of 200 IU/Kg by one or two bolus injections daily.The choice of product brand will be based on physician / patients preferences.
Trial: NCT03471442
Drug: General anesthetic
RxNorm normalized name: General anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia administered as per preference of intra-operative attending anesthesiologist
Trial: NCT03471442
Drug: Opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-operatively, opioids will be titrated to heart rate and spontaneous respiration rate e.g. fentanyl, morphine, hydromorphone. Post-operatively in post anesthesia care unit, morphine and hydromorphone will be titrated to effect as necessary. After discharge from post anesthesia care unit, oral analgesia will be administered on an as required basis e.g. acetaminophen, non-steroid anti-inflammatory medications, acetaminophen / codeine and acetaminophen / oxycodone.
Trial: NCT03471442
Drug: Anesthetics, Local
RxNorm normalized name: ANESTHETICS, LOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based dosing of this local anesthetic mixture.
Trial: NCT01333709
Drug: Induction trichemotherapy - FOLFIRINOX regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A short (4 cycles) and intensive trichemotherapy combinig irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2, 5-Fu (bolus 400 mg/m2, followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered for 8 weeks (D1=D15).
Trial: NCT00775840
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan matching-placebo tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
Trial: NCT00508404
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m², leucovorin 400 mg/m², 5-fluorouracil bolus 400 mg/m², 5-fluorouracil infusion 2400 mg/m².
Trial: NCT04326894
Drug: 25 mg/week oral methotrexate tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00603018
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 weeks of fluoxetine(2.5mg,5mg,10mg,20mg,30mg,40mg,40mg,40mg)each week per day.
Trial: NCT05516225
Drug: PBCLN-003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human Milk Oligosaccharide Concentrate
Trial: NCT02857530
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: without rhTPO
Trial: NCT00720512
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00720512
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03020875
Drug: Per Os Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered acetaminophen.
Trial: NCT00038597
Drug: SCH66336
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00046852
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02525744
Drug: LY900014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00466661
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tabs po TID
Trial: NCT00742872
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet (identical in shape and form to the actual drug) taken orally three times per day (15 min before meals) for 8 weeks.
Trial: NCT01070667
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet once per day for 3 months. The tablet will appear identical to the active dronedarone tablet.
Trial: NCT00226668
Drug: placebo hCRF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo hCRF 2mg/day, dexamethasone 4mg/day and any open-label dexamethasone they may be taking
Trial: NCT03036384
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5µg sufentanyl
Trial: NCT00794638
Drug: SyB L-0501
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The administration of SyB L-0501 90 mg/m2 or 120 mg/m2/day on Day 2 and Day 3 will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).
Trial: NCT04086212
Drug: EXTRANEAL 7.5G/100Ml Peritoneal Dialysis Solution
RxNorm normalized name: EXTRANEAL 7.5g/100ml Peritoneal Dialysis Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a long dwell exchange for three days.
Trial: NCT00461656
Drug: Preoperative conjunctival irrigation with 5% or 1.25% PI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before initiation of surgery, children will have their conjunctival fornices irrigated with 5 ml PI 5% or with 5 ml PI 1.25%
Trial: NCT03409107
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daprodustat matching placebo will be available as 9 mm or 7 mm film coated tablets. Placebo will be administered once daily via oral route and can be taken without regard to food.
Trial: NCT03409107
Drug: Iron therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron therapy will be administered if ferritin is \<50 Nano gram per milliliter and/or TSAT is \<15 percent.
Trial: NCT01176695
Drug: MCT/LCT containing lipid emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medium chain triglycerides, long chain triglycerides
Trial: NCT01968707
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically.
Trial: NCT01968707
Drug: 3M CHG/IPA Prep Tint 10.5-mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically.
Trial: NCT01968707
Drug: 3M CHG/IPA Prep Tint 26-mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically
Trial: NCT00220649
Drug: gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03451695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group will receive 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and normal saline (0.1ml)
Trial: NCT00857077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02161354
Drug: NTC-510 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to one of 3 groups and NTC-510 will be given as a single oral dose of 2.0 mg, a split dose of 2.0 mg followed by 2.0 mg an hour later, or 6.0 mg for acute pain relief (PR) following third molar extraction.
Trial: NCT02161354
Drug: Placebo Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to one of 3 groups and placebo capsules will be given as a single oral dose of for acute dental pain following third molar extraction.
Trial: NCT02161354
Drug: NTC-510A Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to one of 3 groups where NTC-510A or placebo will be given as a single oral dose of 2.0, 4.0, or 6 mg for acute pain relief (PR) following third molar extraction
Trial: NCT00391170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01989793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given to those in placebo arm
Trial: NCT02395237
Drug: : Amaryl® M IR 2/1000
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01621880
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the corticosteroid group were treated with intravenous pulsed-steroid therapy: methylprednisolone 500 mg daily intravenously for three consecutive days followed by oral prednisone 60 mg for five days and gradually tapered 15mg every 5 days. When the prednisone dose reached 30mg per day, it was tapered down more slowly (tapered 5mg every week), until a maintenance dose of 10mg per day was reached. The entire intervention lasted two months. At 2 months, prednisone was stopped.
Trial: NCT00005889
Drug: alanine
RxNorm normalized name: Alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02991118
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
Trial: NCT00005889
Drug: leucine
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005889
Drug: urea
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no